Krystal Biotech (NASDAQ:KRYS) and BioAtla (NASDAQ:BCAB) Head to Head Analysis

BioAtla (NASDAQ:BCAB) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares BioAtla and Krystal Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	-1,177.18%	-200.66%
Krystal Biotech	52.64%	18.69%	17.12%

Earnings & Valuation

This table compares BioAtla and Krystal Biotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$11.00 million	0.88	-$69.78 million	($1.15)	-0.13
Krystal Biotech	$389.13 million	18.43	$204.83 million	$6.85	35.82

Krystal Biotech has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

77.2% of BioAtla shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 11.8% of BioAtla shares are held by insiders. Comparatively, 13.7% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

BioAtla has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioAtla and Krystal Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1	2	1	0	2.00
Krystal Biotech	0	3	8	0	2.73

BioAtla presently has a consensus target price of $4.00, indicating a potential upside of 2,510.97%. Krystal Biotech has a consensus target price of $326.25, indicating a potential upside of 32.95%. Given BioAtla’s higher probable upside, equities analysts plainly believe BioAtla is more favorable than Krystal Biotech.

Summary

Krystal Biotech beats BioAtla on 12 of the 14 factors compared between the two stocks.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.